Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open, Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac Hausstaubmilbe in Patients With HDM-induced Rhinoconjunctivitis With or Without Allergic Asthma

Next Previous
Trial Profile

A Prospective, Open, Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac Hausstaubmilbe in Patients With HDM-induced Rhinoconjunctivitis With or Without Allergic Asthma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 May 2018

At a glance

  • Drugs House dust mite allergy immunotherapy Allergy Therapeutics (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions

    • Most Recent Events

    • 03 May 2018 Planned End Date changed from 30 Sep 2017 to 31 Dec 2018.
    • 03 May 2018 Planned primary completion date changed from 30 Sep 2017 to 31 Dec 2018.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top